Modulation of eCB activity, using new-generation CB1R antagonists and also improvement of lifestyle factors, may serve as complex therapy for obesity-related metabolic disorders, such as IR and diabetes mellitus. This evidence concerns the gene CNR1 and diabetes mellitus.